Skip to content

Search

RSV responsible for one out of every 50 childhood deaths worldwide

The urgency for a world-first respiratory syncytial virus vaccine is at an all-time high.

WA Health funding supports development of rapid test for antibiotic-resistant skin infections in Aboriginal children

A rapid test to detect antibiotic-resistant skin infections in Aboriginal children could be a step closer, thanks to support from the FHRIF.

Help shape the future of health & medical research in your community

Find out what our communities had to say about the draft Statement on Consumers and Community Involvement in Health and Medical Research.

World-first trial to seek child-specific treatments for dangerous bloodstream infections

The Kids Research Institute Australia, Perth Children’s Hospital (PCH) and the Peter Doherty Institute for Infection and Immunity (Doherty Institute) will spearhead the paediatric arm of a world-first global platform trial designed to uncover treatments for Staphylococcus aureus bloodstream infection.

Study confirms maternal whooping cough vaccine protects babies at critical age

A The Kids Research Institute Australia and Curtin University-led study has found the maternal whooping cough vaccine given to pregnant mothers in the second or third trimester significantly reduced babies’ risk of infection, protecting them at their most vulnerable age.

Driving a vaccine revolution

The Kids Research Institute Australia is now part of an ambitious, yet achievable, global bid to produce such one-shot vaccines.

New healthy skin guide for health sector to identify and treat skin issues

A new National Healthy Skin Guideline has been launched by The Kids Research Institute Australia, to help health care providers identify, diagnose and treat a range of skin conditions experienced by Aboriginal and Torres Strait Islander people in urban and remote areas.

Ultra-short course, high-dose primaquine to prevent Plasmodium vivax infection following uncomplicated pediatric malaria: A randomized, open-label, non-inferiority trial of early versus delayed treatment

We aimed to assess safety, tolerability, and Plasmodium vivax relapse rates of ultra-short course (3.5 days) high-dose (1 mg/kg twice daily) primaquine (PQ) for uncomplicated malaria because of any Plasmodium species in children randomized to early- or delayed treatment.

A surge in human metapneumovirus paediatric respiratory admissions in Western Australia following the reduction of SARS-CoV-2 non-pharmaceutical interventions

Western Australian laboratory data demonstrated a decrease in human metapneumovirus detections through 2020 associated with SARS-CoV-2-related non-pharmaceutical interventions, followed by a subsequent surge in metropolitan region in mid-2021. We aimed to assess the impact of the surge in hMPV on paediatric hospital admissions and the contribution of changes in testing.